Drug Discovery World

AUGUST 7, 2023

Research published in Science shows that a naturally occurring bacterium discovered by GSK scientists – Delftia tsuruhatensis Tres Cantos 1 (TC1) – could be the basis for new anti-malarial interventions. “We hope to provide a viable solution that can be readily adopted in field settings.” ovale and P. falciparum).

Bacteria 52

Bacteria Bacterium Containment Scientist 52

Pfizer

JANUARY 27, 2023

That is why, for more than two decades, Pfizer has proudly joined researchers, global health partners and dozens of governments in efforts to eliminate trachoma,” said Caroline Roan, Senior Vice President, Global Health & Social Impact, Pfizer. “We Trachoma is a neglected tropical disease (NTD) caused by the bacterium Chlamydia trachomatis.

Bacteria 75

Bacteria Medicine Containment Manufacturing 75

The Pharma Data

NOVEMBER 26, 2020

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.? For more information, refer to [link].

Containment 52

Containment Bacterium Development Sales 52

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. It contains the antiviral medications nirmatrelvir and ritonavir. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98